ATC codes:
J01DB01
EMLc
Indication
Bacterial cellulitis, erysipelas or lymphangitis
ICD11 code:
1C00
INN
Cefalexin
Medicine type
Chemical agent
Antibiotic groups
List type
Core
Formulations
Oral > Liquid:
125 mg per 5 mL (anhydrous) powder for oral liquid ;
250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (as monohydrate) ; 500 mg (as monohydrate) (EML)
Oral > Solid > dispersible tablet: 125 mg (EMLc) ; 250 mg (EMLc)
Oral > Solid: 250 mg (as monohydrate) ; 500 mg (as monohydrate) (EML)
Oral > Solid > dispersible tablet: 125 mg (EMLc) ; 250 mg (EMLc)
EML status history
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Wikipedia
DrugBank
Expert Committee recommendation
The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children.
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc.
- the addition of new formulations of cefalexin (dispersible tablet 125 mg and 250 mg) to the EMLc.
- the addition of new strength formulations of cloxacillin (capsule 250 mg, powder for injection 250 mg (as sodium) and powder for oral liquid 250 mg/5 mL (as sodium) on the EMLc.
EML recommendations: Bacterial cellulitis, erysipelas or lymphangitis
First choice
Second choice